Human Genome Rejects GSK's $2.6B Bid With Poison Pill
Drugmaker Human Genome Sciences Inc. has blocked an unsolicited $2.59 billion takeover bid by GlaxoSmithKline PLC on Thursday with a poison pill plan that will deter the health care giant from...To view the full article, register now.
Already a subscriber? Click here to view full article